29 November 2022: Clinical Research
Sex-Related Differences in Sitagliptin Treatment in Type 2 Diabetes: Results from the PROLOGUE Trial
Xilin Wu 1ABCDEF , Shiming Zhang 1ABCEF , Yingzhu Jin 2ABC , Xun Xiao 3ABCDEF*DOI: 10.12659/MSM.938030
Med Sci Monit 2022; 28:e938030
Table 1 Baseline characteristics of male participants.
| Characteristic | Sitagliptin group | Conventional group | P-value |
|---|---|---|---|
| N | 146 | 151 | |
| Age, years | 68.21±9.22 | 68.66±9.24 | 0.670 |
| Height, cm | 164.55±6.66 | 165.06±5.50 | 0.479 |
| Weight, kg | 68.89±10.69 | 68.04±10.82 | 0.498 |
| Body mass index, kg/m | 25.20±3.49 | 25.10±3.91 | 0.834 |
| Waist circumference, (cm) | 90.98±9.52 | 89.67±9.71 | 0.267 |
| Systolic blood pressure, mmHg | 130.01±16.22 | 127.77±15.83 | 0.231 |
| Diastolic blood pressure, mmHg | 73.66±10.34 | 72.62±11.33 | 0.409 |
| HbA1c,% | 6.54±0.52 | 6.57±0.52 | 0.593 |
| Fasting plasma glucose, mmol/l | 141.75±44.04 | 135.86±34.48 | 0.210 |
| Serum creatinine, μmol/l | 0.93±0.22 | 0.94±0.25 | 0.649 |
| Estimated glomerular filtration rate, ml/min/1.73 m | 66.43±16.47 | 65.91±16.65 | 0.786 |
| Hypertension, N (%) | 121 (82.88%) | 116 (76.82%) | 0.194 |
| Dyslipidemia, N (%) | 105 (71.92%) | 99 (65.56%) | 0.238 |
| Cerebral infarction, N (%) | 11 (7.53%) | 17 (11.26%) | 0.272 |
| Cerebral hemorrhage, N (%) | 2 (1.37%) | 1 (0.66%) | 0.542 |
| Myocardial infarction, N (%) | 39 (26.71%) | 49 (32.45%) | 0.279 |
| Arrhythmia, N (%) | 20 (13.70%) | 25 (16.56%) | 0.492 |
| Chronic heart failure, N (%) | 12 (8.22%) | 19 (12.58%) | 0.219 |
| Percutaneous coronary intervention, N (%) | 45 (30.82%) | 51 (33.77%) | 0.586 |
| Coronary artery bypass grafting, N (%) | 15 (10.27%) | 15 (9.93%) | 0.923 |